CDMO vs. ZLAB, MTSR, DNLI, XENE, MOR, TWST, VCEL, CPRX, MLTX, and MRUS
Should you be buying Avid Bioservices stock or one of its competitors? The main competitors of Avid Bioservices include Zai Lab (ZLAB), Metsera (MTSR), Denali Therapeutics (DNLI), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry.
Avid Bioservices vs.
Zai Lab (NASDAQ:ZLAB) and Avid Bioservices (NASDAQ:CDMO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
Zai Lab has a net margin of -76.14% compared to Avid Bioservices' net margin of -101.07%. Avid Bioservices' return on equity of -33.18% beat Zai Lab's return on equity.
Zai Lab has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Avid Bioservices received 143 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 65.95% of users gave Avid Bioservices an outperform vote while only 64.31% of users gave Zai Lab an outperform vote.
Avid Bioservices has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Avid Bioservices, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zai Lab had 7 more articles in the media than Avid Bioservices. MarketBeat recorded 8 mentions for Zai Lab and 1 mentions for Avid Bioservices. Zai Lab's average media sentiment score of 0.69 beat Avid Bioservices' score of 0.10 indicating that Zai Lab is being referred to more favorably in the media.
41.7% of Zai Lab shares are held by institutional investors. Comparatively, 97.2% of Avid Bioservices shares are held by institutional investors. 13.9% of Zai Lab shares are held by insiders. Comparatively, 3.1% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Zai Lab presently has a consensus price target of $55.00, suggesting a potential upside of 62.82%. Avid Bioservices has a consensus price target of $12.25, suggesting a potential downside of 1.96%. Given Zai Lab's stronger consensus rating and higher possible upside, research analysts plainly believe Zai Lab is more favorable than Avid Bioservices.
Summary
Zai Lab beats Avid Bioservices on 10 of the 19 factors compared between the two stocks.
Get Avid Bioservices News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avid Bioservices Competitors List
Related Companies and Tools
This page (NASDAQ:CDMO) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CDMO Stock Alerts